Novaccess Global Inc XSNX

Healthcare Biotechnology

NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.

OTCQB:XSNX - Post by User

Novaccess Global Inc > There you go ...to .001c again..

<< Previous

Bullboard Posts

Next >>

Post by Sonali1997on Jun 20, 2018 11:10am

130 Views

Post# 28198755

There you go ...to .001c again..

Recent Trades - Last 10 of 32 Time ET Ex Price Change Volume 10:48:39 Q 0.0018 -0.0004 300,000 10:46:32 Q 0.0018 -0.0004 283,500 10:46:10 Q 0.0018 -0.0004 706,500 10:46:10 Q 0.0018 -0.0004 10,000 10:24:59 Q 0.002 -0.0002 40,000 10:23:08 Q 0.0018 -0.0004 85,000 10:23:08 Q 0.0018 -0.0004 65,000 10:22:15 Q 0.0018 -0.0004 300,000 10:20:41 Q 0.0018 -0.0004 228,500 10:20:40 Q 0.0019 -0.0003 21,500

<< Previous

Bullboard Posts

Next >>

High Tide adds two stores to undervalued cannabis retail network